A further interesting result pertains to VEGFR-TKI plus ICI combinations, the current first-choice treatment option recommended by international guidelines [33, 34] for the majority of patients with metastatic ccRCC. The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.